Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking

Drug Testing and Analysis

Volumn 7, Issue 6, 2015, Pages 494-501

  Lee, Dayong ^a   Vandrey, Ryan ^b   Mendu, Damodara R ^a   Murray, Jeannie A ^b   Barnes, Allan J ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoid; Cannabis; Delta 9 tetrahydrocannabinol; Oral fluid

Indexed keywords

AD LIBITUM; CANNABINOIDS; CANNABINOL; CANNABIS; DELTA-9-TETRAHYDROCANNABINOL; DETECTION RATES; DRUG TESTING; ORAL FLUIDS; SAMPLE COLLECTION; SIMPLE++;

CANNABINOL; DRONABINOL; TETRAHYDROCANNABINOLIC ACID; 11-NOR-DELTA(9)-TETRAHYDROCANNABINOL-9-CARBOXYLIC ACID; CANNABIDIOL; CANNABINOID;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD ANALYSIS; BODY MASS; CANNABIS SMOKING; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); DEMOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MIDDLE AGED; PHYSICAL TOLERANCE; PRIORITY JOURNAL; SMOKING HABIT; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; DRUG SELF ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; SALIVA; SUBSTANCE ABUSE; TIME FACTOR;

ADMINISTRATION, ORAL; ADULT; CANNABIDIOL; CANNABINOIDS; CANNABINOL; DRONABINOL; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; SALIVA; SELF ADMINISTRATION; SUBSTANCE ABUSE DETECTION; TIME FACTORS;

EID: 84930274533     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1718     Document Type: Article

References (35)

1. R. S. Niedbala, K. W. Kardos, D. F. Fritch, S. Kardos, T. Fries, J. Waga, J. Robb, E. J. Cone. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J. Anal. Toxicol. 2001, 25, 289.
2. G. F. Kauert, J. G. Ramaekers, E. Schneider, M. R. Moeller, S. W. Toennes. Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J. Anal. Toxicol. 2007, 31, 288.
3. 9-tetrahydrocannabinold concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J. Anal. Toxicol. 2004, 28, 394.
4. G. Milman, D. M. Schwope, D. A. Gorelick, M. A. Huestis. Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clin. Chim. Acta 2012, 413, 765.
5. D. Lee, D. M. Schwope, G. Milman, A. J. Barnes, D. A. Gorelick, M. A. Huestis. Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin. Chem. 2012, 58, 748.
6. S. Niedbala, K. Kardos, S. Salamone, D. Fritch, M. Bronsgeest, E. J. Cone. Passive cannabis smoke exposure and oral fluid testing. J. Anal. Toxicol. 2004, 28, 546.
7. D. Lee, G. Milman, A. J. Barnes, R. S. Goodwin, J. Hirvonen, M. A. Huestis. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin. Chem. 2011, 57, 1127.
8. C. Moore, S. Rana, C. Coulter. Simultaneous identification of 2-carboxy-tetrahydrocannabinol, tetrahydrocannabinol, cannabinol and cannabidiol in oral fluid. J. Chromatogr. B 2007, 852, 459.
9. C. Moore, S. Rana, C. Coulter, D. Day, M. Vincent, J. Soares. Detection of conjugated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid. J. Anal. Toxicol. 2007, 31, 187.
10. S. W. Toennes, J. G. Ramaekers, E. L. Theunissen, M. R. Moeller, G. F. Kauert. Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J. Anal. Toxicol. 2010, 34, 216.
11. J. Copeland, W. Swift, V. Rees. Clinical profile of participants in a brief intervention program for cannabis use disorder. J. Subst. Abuse Treat. 2001, 20, 45.
12. M. Haney, A. S. Ward, S. D. Comer, R. W. Foltin, M. W. Fischman. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 1999, 141, 395.
13. D. S. Hasin, K. M. Keyes, D. Alderson, S. Wang, E. Aharonovich, B. F. Grant. Cannabis withdrawal in the United States: Results from NESARC. J. Clin. Psychiat. 2008, 69, 1354.
14. E. J. Cone, J. Clarke, L. Tsanaclis. Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid. J. Anal. Toxicol. 2007, 31, 424.
15. R. Heltsley, A. DePriest, D. L. Black, T. Robert, L. Marshall, V. M. Meadors, Y. H. Caplan, E. J. Cone. Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J. Anal. Toxicol. 2011, 35, 529.
16. H. Gjerde, A. S. Christophersen, I. S. Moan, B. Yttredal, J. M. Walsh, P. T. Normann, J. Mørland. Use of alcohol and drugs by Norwegian employees: A pilot study using questionnaires and analysis of oral fluid. J. Occup. Med. Toxicol. 2010, 5, 1.
17. O. H. Drummer, D. Gerostamoulos, M. Chu, P. Swann, M. Boorman, I. Cairns. Drugs in oral fluid in randomly selected drivers. Forensic Sci. Int. 2007, 170, 105.
18. K. W. Simonsen, A. Steentoft, T. Hels, I. M. Bernhoft, B. S. Rasmussen, K. Linnet. Presence of psychoactive substances in oral fluid from randomly selected drivers in Denmark. Forensic Sci. Int. 2012, 221, 33.
19. R. Vandrey, M. L. Stitzer, M. Z. Mintzer, M. A. Huestis, J. A. Murray, D. Lee. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2012, 128, 64.
20. G. Milman, A. J. Barnes, R. H. Lowe, M. A. Huestis. Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J. Chromatogr. A 2010, 1217, 1513.
21. R. H. Lowe, E. L. Karschner, E. W. Schwilke, A. J. Barnes, M. A. Huestis. Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J. Chromatogr. A 2007, 1163, 318.
22. G. Milman, M. M. Bergamaschi, D. Lee, D. R. Mendu, A. J. Barnes, R. Vandrey, M. A. Huestis. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. Ther. Drug Monit. 2014, 36, 218.
23. H. W. Uh, F. C. Hartgers, M. Yazdanbakhsh, J. J. Houwing-Duistermaat. Evaluation of regression methods when immunological measurements are constrained by detection limits. BMC Immunol. 2008, 9, 1.
24. S. Anizan, G. Milman, N. Desrosiers, A. J. Barnes, D. A. Gorelick, M. A. Huestis. Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Anal. Bioanal. Chem. 2013, 405, 8451.
25. M. N. Newmeyer, N. A. Desrosiers, D. Lee, D. R. Mendu, A. J. Barnes, D. A. Gorelick, M. A. Huestis. Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test. Anal. 2014, Epub ahead of print.
26. D. C. D'Souza, M. Ranganathan, G. Braley, R. Gueorguieva, Z. Zimolo, T. Cooper, E. Perry, J. Krystal. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33, 2505.
27. S. González, M. Cebeira, J. Fernández-Ruiz. Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacol. Biochem. Behav. 2005, 81, 300.
28. J. G. Ramaekers, E. L. Theunissen, M. de Brouwer, S. W. Toennes, M. R. Moeller, G. Kauert. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl) 2011, 214, 391.
29. J. Hirvonen, R. S. Goodwin, C. T. Li, G. E. Terry, S. S. Zoghbi, C. Morse, V. W. Pike, N. D. Volkow, M. A. Huestis, R. B. Innis. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiat. 2012, 17, 642.
30. G. Milman, D. M. Schwope, E. W. Schwilke, W. D. Darwin, D. L. Kelly, R. S. Goodwin, D. A. Gorelick, M. A. Huestis. Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral delta9-tetrahydrocannabinol administration. Clin. Chem. 2011, 57, 1597.
31. D. Lee, R. Vandrey, D. R. Mendu, S. Anizan, G. Milman, J. A. Murray, A. J. Barnes, M. A. Huestis. Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. Clin. Chem. 2013, 59, 1770.
32. J. H. Mendelson, N. K. Mello, B. W. Lex, S. Bavli. Marijuana withdrawal syndrome in a woman. Am. J. Psychiat. 1984, 141, 1289.
33. D. P. Tashkin, B. J. Shapiro, Y. E. Lee, C. E. Harper. Subacute effects of heavy marihuana smoking on pulmonary function in healthy men. New Engl. J. Med. 1976, 294, 125.
34. A. Georgotas, P. Zeidenberg. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr. Psychiat. 1979, 20, 427.
35. E. A. McClure, M. L. Stitzer, R. Vandrey. Characterizing smoking topography of cannabis in heavy users. Psychopharmacology (Berl) 2012, 220, 309.